-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sodium-glucose co-transport protein-2 (SGLT-2) inhibitors and glutatrogytin-like peptide-1 (GLP-1) inhibitors are widely used diabetes drugs in clinical practice, in addition to good blood sugar control effects, it has traditional diabetes treatment drugs do not have the advantage of reducing the risk of cardiovascular mortality and non-fatal cardiovascular complications in diabetic patients.
researchers recently compared the differences in the effectiveness of treatment for patients with diabetes with different cardiovascular and kidney risks.
This study is a systematic review and meta-analysis that collects data from Medline, Embase, and Cochrane CENTRAL as of August 11, 2020, and is selected to compare SGLT-2 inhibitors or GLP-1 subject agonists with placebos, standard care, or other sugar-lowering treatments for clinically controlled studies of type 2 diabetes in adults for at least 24 weeks.
Patients' cardiovascular risk within 5 years was classified as very low (no risk factors), low (more than 3 risk factors), moderate (with cardiovascular disease), high (with chronic kidney disease) and very high (with both cardiovascular disease and chronic kidney disease).
764 studies were included in this meta-analysis, which included a total of 421,346 patients.
SGLT-2 inhibitors and GLP-1 perceptors reduce the risk of all-cause death, cardiovascular death, non-fatal myocardial infarction, and kidney failure in diabetic patients.
study found that SGLT-2 inhibitors were better at reducing hospitalization and mortality from heart failure than GLP-1-1 agonists, while GLP-1 inhibitors were better at reducing non-fatal strokes than SGLT-2 inhibitors, but SGLT-2 inhibitors had a higher risk of urinary tract infections, while GLP-1 inhibitors had a higher risk of gastrointestinal events.
There is evidence that SGLT-2 inhibitors and GLP-1-1 subjector agitants are beneficial for improving weight in patients, but there is no significant advantage in reducing diabetes complications such as amputation, blindness, eye disease, neuropathy, or health-related quality of life.
study found that SGLT-2 inhibitors and GLP-1-1 subjector astrists reduced the risk of cardiovascular and kidney events in diabetic patients.
